Low clinical value in repeat latent tuberculosis tests in patients taking biologics

ATLANTA — Repeat, routine testing for latent tuberculosis infection among patients receiving biologics is both costly and of low clinical value, according to findings presented at the 2019 ACR/ARP Annual Meeting.“The CDC in 2010 recommended that the QuantiFERON TB can essentially replace the TST in all situations where a TB screening is required,” Urmi Khanna, MD, of the Cleveland Clinic, told attendees. “So, how frequently should we screen our patients who are on biologics for latent TB infection? All patients should definitely be screened at baseline, but theRead More

Share on facebook
Share on twitter
Share on linkedin